362670-19-7

Basic information

• Product Name: 7-(4-BIPHENYL)-7-OXOHEPTANOIC ACID
• Synonyms: 7-(4-BIPHENYL)-7-OXOHEPTANOIC ACID
• CAS NO: 362670-19-7
• Molecular Formula: C₁₉H₂₀O₃
• Molecular Weight: 296.36
• Mol File: 362670-19-7.mol

Chemical Properties

• Boiling Point: 501.2°C at 760 mmHg
• Flash Point: 271°C
• Appearance: /
• Density: 1.125g/cm³
• Vapor Pressure: 7.24E-11mmHg at 25°C
• Refractive Index: 1.563
• CAS DataBase Reference: 7-(4-BIPHENYL)-7-OXOHEPTANOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 7-(4-BIPHENYL)-7-OXOHEPTANOIC ACID(362670-19-7)
• EPA Substance Registry System: 7-(4-BIPHENYL)-7-OXOHEPTANOIC ACID(362670-19-7)

Safety Data

• Hazardous Substances Data: 362670-19-7(Hazardous Substances Data)

Usage

InChI:InChI=1/C19H20O3/c20-18(9-5-2-6-10-19(21)22)17-13-11-16(12-14-17)15-7-3-1-4-8-15/h1,3-4,7-8,11-14H,2,5-6,9-10H2,(H,21,22)

Upstream product

• 92-52-4 biphenyl 
• 10521-07-0 pimelic acid anhydride 
• 111-16-0 heptanedioic acid 
• 25308-75-2 1-Phenylcycloheptene 

Relevant articles and documents

Structure-activity relationship of a new series of reversible dual monoacylglycerol lipase/fatty acid amide hydrolase inhibitors

The two endocannabinoids, anandamide (AEA) and 2-arachidonoylglycerol (2-AG), play independent and nonredundant roles in the body. This makes the development of both selective and dual inhibitors of their inactivation an important priority. In this work we report a new series of inhibitors of monoacylglycerol lipase (MAGL) and fatty acid amide hydrolase (FAAH). Among them, (±)-oxiran-2-ylmethyl 6-(1,1′-biphenyl-4-yl)hexanoate (8) and (2R)-(-)-oxiran-2-ylmethyl(4-benzylphenyl)acetate (30) stand out as potent inhibitors of human recombinant MAGL (IC50 (8) = 4.1 μM; IC 50 (30) = 2.4 μM), rat brain monoacylglycerol hydrolysis (IC 50 (8) = 1.8 μM; IC50 (30) = 0.68 μM), and rat brain FAAH (IC50 (8) = 5.1 μM; IC50 (30) = 0.29 μM). Importantly, and in contrast to the other previously described MAGL inhibitors, these compounds behave as reversible inhibitors either of competitive (8) or noncompetitive nature (30). Hence, they could be useful to explore the therapeutic potential of reversible MAGL inhibitors.

Inhibitors of histone deacetylase

The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.